Market cap
$16.1m
End-of-day close multiplied by current shares on issue.
TRU · NZX
Truscreen Group is an NZX-listed healthcare / medical diagnostics company with HY22 - FY26 of published result briefings.
Snapshot
FY26, released 29 May 2026
| Metric | Value | Change |
|---|---|---|
| Revenue | $2.4m | ↑ +45.0% |
| EBITDA | -$2.2m | — |
| NPAT | -$2.3m | ↑ +70.9% |
| Operating cash flow | -$2.5m | ↑ +2.4% |
| OCF / EBITDA % | 112.3% | — |
| ROE % | -87.1% | — |
| PBT | -$2.3m | ↑ +70.9% |
| FCF pre-lease | -$2.5m | ↑ +2.5% |
| Debtor days | 154 | ↑ +157.0% |
| Inventory days | 99 | ↓ -8.4% |
Source: latest published briefing (FY26, released 29 May 2026). Change compares against the prior equivalent period: FY22, released 30 May 2022.
Valuation
A compact read on what the market price implies next to the latest filing data. The numbers are a starting point for comparison, not a recommendation.
The latest close and share count context for the market price.
Market cap
$16.1m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not meaningful when recent earnings are negative.
EPS
-0.00
Recent filing-derived earnings per share.
PEG
Not available
Not available for this company right now.
EV/EBITDA
Not available
Not meaningful when recent EBITDA is negative.
P/FCF
Not available
Not meaningful when free cash flow is negative or unavailable.
P/B
6.23x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Daily closes use the full available width, with hover and touch readouts against real observations. Expand opens the chart at reading size.
Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.
Chat
Ask follow-up questions about Truscreen Group's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Longitudinal view
The latest period is shown first.
| Metric | FY2612 MONTHS29 May 2026 | HY236 MONTHS29 November 2022 | FY2212 MONTHS30 May 2022 | HY226 MONTHS29 November 2021 | Trend |
|---|---|---|---|---|---|
| Revenue | $2.4m | $0.74m | $1.7m | $0.75m | Chart |
| Revenue growth % | 42.2% | -0.7% | 48.2% | 24.8% | Chart |
| EBITDA | -$2.2m | -$1.2m | — | -$1.3m | Chart |
| EBITDA margin % | -90.4% | -164.9% | — | -169.0% | Chart |
| PBT | -$2.3m | -$1.2m | -$7.9m | -$1.3m | Chart |
| NPAT | -$2.3m | -$1.2m | -$7.9m | -$1.3m | Chart |
| Operating cash flow | -$2.5m | -$1.2m | -$2.5m | -$1.7m | Chart |
| OCF / EBITDA % | 112.3% | 99.7% | — | 136.6% | Chart |
| FCF pre-lease | -$2.5m | -$1.2m | -$2.5m | -$1.7m | Chart |
| FCF post-lease | — | -$1.2m | — | -$1.7m | Chart |
| DPS | — | 0.0c | — | 0.0c | Chart |
| ROE % | -87.1% | -51.9% | n/m | -13.0% | Chart |
| Net debt | — | — | — | -$3.7m | — |
| Net debt / EBITDA | — | — | — | 2.92x | — |
| Debtor days | 154 | 37 | 60 | 2 | Chart |
| Inventory days | 99 | 174 | 108 | 169 | Chart |
| Total assets | $3.7m | $2.9m | $4.4m | $10.3m | Chart |
Reference: annolyse.ai/companies/tru
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Reported revenue across covered periods.
Like-period revenue growth where comparable.
Company-specific earnings measure where disclosed.
EBITDA-equivalent margin where revenue and earnings are source-backed.
Statutory profit after tax.
Cash generated from operations.
Additional verified filing metrics for this company. Each point links back to a published briefing period in the source data contract.
Operating cash flow less capex before leases.
Free cash flow after lease payments where available.
Return on equity.
Borrowings less cash; negative values indicate net cash.
Dividend per share declared for the period.
Receivables days where the working-capital inputs are source-backed.
Inventory days where the working-capital inputs are source-backed.
The setup & the reality
The latest result is checked against what the prior briefing said to watch.
Historical setup
Previous analysisHY23Result releasedAnnolyse analysis published
From Cash down to $1.7m as $1.2m HY operating burn continues
No forward revenue or earnings target is provided in the release. The FY22 shape is not a clean seasonality guide: HY22 carried 44.4% of FY22 revenue but only 16% of FY22 NPAT, and that asymmetry sits in the FY22 impairment booked in the second half rather than a recurring 2H business pattern. On revenue alone, an annualised run-rate of approximately $1.5m sits below FY22 product revenue of $1.7m, so matching last year would require a stronger second half.
Management commentary cites China lockdown disruption and continued expansion in private health-check channels but provides no quantified outlook against which this half can be judged.
Open questions
This briefing cannot assess management's specific cash runway forecast or capital plan because no quantified outlook or funding guidance was disclosed.
Archive
Every published Annolyse briefing for this company appears here in reverse chronological order.
FY26 · Released 29 May 2026
A 140bps gross margin lift is real, but a $1.0m receivables build and ongoing $2.5m operating cash burn keep the runway question open.
HY23 · Released 29 November 2022
Operating cash outflow narrowed 29.3% to $1.2m, but at $0.74m half-year revenue, runway is now the central question.
FY22 · Released 30 May 2022
Operating leverage moved the wrong way in the second half, with the implied H2 loss running roughly five times H1 and cash burn consuming nearly half
HY22 · Released 29 November 2021
Reported loss narrowed in dollar terms but operating cash outflow grew, drawing cash down 17.8% and total equity 13.4% over the period.
Get the next Truscreen Group result briefing and five-year history updates by email.